JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure — Stella

Home/Severe Aplastic Anemia/

View on ClinicalTrials.gov

Recruiting

Back to Severe Aplastic Anemia trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

National Institutes of Health Clinical Center, Bethesda, Maryland

Key details

Phase

Early testing / Safety & dosing

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Enrollment target

~145 participants

Started

February 2024

Primary completion

June 2030

Age range

18 Years – 99 Years

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.